The priority that will unite all life sciences companies in 2016 is the pursuit of greater agility. As long as organisations keep taking a short-term view, investing in standalone information management systems for each new business requirement, the only thing they’ll successfully grow is cost, warns Mark Evenepoel, Group CEO at Amplexor Life Sciences. The real focus should be flexibility and responsiveness to whatever the market demands next.
The post Why Agility Holds the Key to Transformation in Life Sciences appeared first on IPI International Pharmaceutical Industry.